Geron/$GERN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Geron
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Ticker
$GERN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
229
ISIN
US3741631036
Website
Geron Metrics
BasicAdvanced
$968M
-
-$0.21
0.76
-
Price and volume
Market cap
$968M
Beta
0.76
52-week high
$5.06
52-week low
$1.17
Average daily volume
11M
Financial strength
Current ratio
7.865
Quick ratio
6.326
Long term debt to equity
86.184
Total debt to equity
86.184
Interest coverage (TTM)
-5.77%
Profitability
EBITDA (TTM)
-133.736
Gross margin (TTM)
8.06%
Net profit margin (TTM)
-119.54%
Operating margin (TTM)
-115.49%
Revenue per employee (TTM)
$510,000
Management effectiveness
Return on assets (TTM)
-16.07%
Return on equity (TTM)
-45.35%
Valuation
Price to revenue (TTM)
8.648
Price to book
3.61
Price to tangible book (TTM)
3.61
Price to free cash flow (TTM)
-4.92
Free cash flow yield (TTM)
-20.33%
Free cash flow per share (TTM)
-30.89%
Growth
Revenue change (TTM)
22,264.04%
Earnings per share change (TTM)
-38.93%
3-year revenue growth (CAGR)
338.53%
10-year revenue growth (CAGR)
57.78%
3-year earnings per share growth (CAGR)
-16.36%
10-year earnings per share growth (CAGR)
-1.02%
What the Analysts think about Geron
Analyst ratings (Buy, Hold, Sell) for Geron stock.
Bulls say / Bears say
Geron Corporation's lead product, Rytelo, achieved $47.5 million in net product revenue in Q4 2024 and $76.5 million since its June 2024 launch, indicating strong initial market uptake. (stocktitan.net)
The company ended 2024 with $502.9 million in cash and equivalents, providing a solid financial foundation for future operations and potential expansion. (stocktitan.net)
Geron received a positive CHMP opinion for Rytelo in Europe, with expected approval in the first half of 2025 and commercialization in select EU countries in 2026, opening new revenue streams. (stocktitan.net)
Geron's stock price declined over 30% following the announcement that Rytelo's growth had flattened, raising concerns about the drug's market performance. (seekingalpha.com)
Multiple class action lawsuits have been filed against Geron, alleging that the company misled investors regarding Rytelo's launch success and growth potential. (tradingview.com)
Analysts have downgraded Geron's earnings estimates, with Leerink Partners reducing their Q4 2025 earnings forecast from $0.02 to ($0.01) per share, reflecting a more pessimistic outlook. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
Geron Financial Performance
Revenues and expenses
Geron Earnings Performance
Company profitability
Geron News
AllArticlesVideos
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 week ago
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 month ago
GERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Geron stock?
Geron (GERN) has a market cap of $968M as of June 26, 2025.
What is the P/E ratio for Geron stock?
The price to earnings (P/E) ratio for Geron (GERN) stock is 0 as of June 26, 2025.
Does Geron stock pay dividends?
No, Geron (GERN) stock does not pay dividends to its shareholders as of June 26, 2025.
When is the next Geron dividend payment date?
Geron (GERN) stock does not pay dividends to its shareholders.
What is the beta indicator for Geron?
Geron (GERN) has a beta rating of 0.76. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.